Abstract
Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have